Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.

doi:10.1111/j.1365-2893.2006.00728.x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.

Journal of viral hepatitis - 1 Sept 2006

Alexopoulou A, Theodorou M, Dourakis S P, Karayiannis P, Sagkana E, Papanikolopoulos K, Archimandritis A J

Abstract excerpt

Hepatitis B virus (HBV) strains carrying the precore stop-codon mutation (A1896) have been considered among the predisposing factors for reactivation during chemotherapy for malignancies. The role of the T1762/A1764 basic core promoter (BCP) mutations has not been fully evaluated. We aimed to record any changes in HBV serological markers after reactivation, detect the presence of A1896 and BCP mutations and...

Topics

Adolescent
Adult
Aged
Antineoplastic Agents
Codon, Terminator
DNA, Viral
Female
Hepatitis B
Hepatitis B Antibodies
Hepatitis B Core Antigens
Hepatitis B Surface Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Hepatitis B e Antigens

Hepatitis B virus

Humans

Male

Middle Aged

Mutation

Neoplasms

Source

Open in PubMed

Identifiers

PMID: 16907845
DOI: 10.1111/j.1365-2893.2006.00728.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.PMID 16907845Read ↗

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important roleSemantic proximity Read ↗

Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy.Semantic proximity Read ↗

Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients.Semantic proximity Read ↗

Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation.Semantic proximity Read ↗

Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.Semantic proximity Read ↗

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.Semantic proximity Read ↗

Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.Semantic proximity Read ↗

Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.Semantic proximity Read ↗

Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen.Semantic proximity Read ↗

Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence.Semantic proximity Read ↗

Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic ChemotherapySemantic proximity Read ↗

Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.